title: Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus.
abstract: Immunogenicity of Varicella-zoster virus glycoproteins gE, gB, gH, and gL expressed by recombinant vaccinia viruses (VV) separately or simultaneously was determined in mice and guinea pigs by ELISA, Western blotting, radioimmunoprecipitation, plaque reduction assay, and skin test. Single VV-gE and VV-gB recombinants and double VV-gH/gL recombinant elicited specific antibodies with VZV neutralizing activity in mice. Co-expression of gE and gB by one recombinant VV resulted in an increased antibody response in comparison with immunization with single recombinants or their mixtures. Unlike anti-gB and anti-gH/gL antibodies, the gE-specific antibodies had no virus neutralizing activity in absence of complement, and when used alone, they even caused considerable increase of VZV infectious units. Moreover, immune sera containing anti-gE antibodies antagonized complement independent virus-neutralizing activity of anti-gB- and anti-gH/gL-positive sera. The ability to induce delayed hypersensitivity reaction to VZV antigens was observed after immunization of guinea pigs with gE- and/or gB-expressing VVs.
authors.affiliation: Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U nemocnice 1, CZ-128 20 Prague 2, Czech Republic.
authors.forename: L
authors.initials: L
authors.lastname: Kutinová
authors.forename: P
authors.initials: P
authors.lastname: Hainz
authors.forename: V
authors.initials: V
authors.lastname: Ludvíková
authors.forename: L
authors.initials: L
authors.lastname: Maresová
authors.forename: S
authors.initials: S
authors.lastname: Nĕmecková
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D003165:Complement System Proteins / Q000276:immunology; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors / Q000276:immunology; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology; D006168:Guinea Pigs; D014645:Herpesvirus 3, Human / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D011995:Recombination, Genetic; D012867:Skin / Q000276:immunology; D012882:Skin Tests; D014616:Vaccinia virus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D010948:Viral Plaque Assay; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C090198:glycoprotein B, varicella-zoster virus; C056913:glycoprotein E, varicella-zoster virus; C094648:glycoprotein gL, varicella-zoster virus; C040496:gp 118 protein, Herpesvirus 3, Human; D003165:Complement System Proteins